Related Experiment Video
Updated: May 16, 2025
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Improved practical value of the FIGO 2023 staging system in evaluating prognosis of early stages endometrial
Qiaoyan Kang1, Jianguo Zhao1, Jiaqi Wang1
1Department of Gynecological Oncology, Tianjin Central Hospital Gynecology Obstetrics, Tianjin, China.
Objective:
To investigate the practical value of the International Federation of Gynecology and Obstetrics (FIGO) 2023 endometrial cancer (EC) staging system.
Methods:
Data on clinicopathological characteristics of patients diagnosed with EC at Tianjin Central Hospital of Gynecology Obstetrics from January 2015 to December 2017 were collected. Initial staging was performed using the FIGO 2009 system, followed by revised staging with the 2023 FIGO system. The oncological outcomes of patients under the different staging systems were analyzed.
Results:
A total of 671 patients with EC were included in this study, and after applying the 2023 FIGO staging system, the staging of 119 (17.73%) patients changed, with 11 (1.64%) patients experiencing downstaging and 108 (16.10%) patients experiencing upstaging; 5-year progression-free survival (PFS) and overall survival (OS) rates changed in stage I (97.75%-98.55% and 98.79%-99.38%, respectively) and stage II (91.39%-93.16% and 95.65%-95.72%, respectively) patients, and the differences in PFS (P = 0.060 and P = 0.001, respectively) and OS (P = 0.349 and P = 0.003, respectively) between stage I and stage II patients became statistically significant. After the restaging of FIGO 2009 stage I patients, there were statistically significant differences in PFS (P = 0.002 and P = 0.024, respectively) and OS (P = 0.002 and P = 0.002, respectively) between stage IIB and IA1 and IA2 patients, and significant differences in PFS (P = 0.022) and OS (P = 0.048) were observed between stage IIC and IA1 patients. In FIGO 2023 stage IIB and IIC patients, the differences in PFS (P = 0.39 and P = 0.39, respectively) and OS (P = 0.78 and P = 0.5, respectively) were not statistically significant among the various FIGO 2009 stages.
Conclusion:
In the FIGO 2023 EC staging system, stage I and II staging criteria are more reasonable, and the addition of stage IIB and IIC helps to better evaluate patient prognosis.
